Signal Transduction and Targeted Therapy (Feb 2021)

Rab22a-NeoF1 fusion protein promotes osteosarcoma lung metastasis through its secretion into exosomes

  • Li Zhong,
  • Dan Liao,
  • Jingjing Li,
  • Wenqiang Liu,
  • Jingxuan Wang,
  • Cuiling Zeng,
  • Xin Wang,
  • Zhiliang Cao,
  • Ruhua Zhang,
  • Miao Li,
  • Kuntai Jiang,
  • Yi-Xin Zeng,
  • Jianhua Sui,
  • Tiebang Kang

DOI
https://doi.org/10.1038/s41392-020-00414-1
Journal volume & issue
Vol. 6, no. 1
pp. 1 – 16

Abstract

Read online

Abstract It remains unknown for decades how some of the therapeutic fusion proteins positive in a small percentage of cancer cells account for patient outcome. Here, we report that osteosarcoma Rab22a-NeoF1 fusion protein, together with its binding partner PYK2, is sorted into exosomes by HSP90 via its KFERQ-like motif (RVLFLN142). The exosomal Rab22a-NeoF1 fusion protein facilitates the pulmonary pre-metastatic niche formation by recruiting bone marrow-derived macrophages. The exosomal PYK2 activates RhoA in its negative recipient osteosarcoma cells and induces signal transducer and activator of transcription 3 activation in its recipient macrophages to increase M2 phenotype. Consequently, lung metastases of its recipient osteosarcoma cells are promoted by this exosomal Rab22a-NeoF1 fusion protein, and this event can be targeted by disrupting its interaction with PYK2 using a designed internalizing RGD peptide.